Argent BioPharma Limited(RGTLF)
USD --+0.00%
Reward38Moderate
Risk68Medium-High
📊75%Data
Revenue down 40% YoY
RGTLF
+0.0 · +0.00%
USD · PINK
Argent BioPharma Limited | Healthcare
Structurally Challenged
Market Cap:5.65M
ℹ️
Reward Rating
38
Moderate
Bottom 5% (model universe)
75% data coverage
ℹ️
Risk Rating
68
Medium-High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on RGTLF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Argent BioPharma Limited?

Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally.

RGTLF · Verdict

Limited reward · elevated risk

RGTLF's standout is volatility; balance sheet and cash flow weigh on the picture.

Based on 88% data coverage

RGTLF · Verdict

What’s working & what to watch

Strengths 1

  • Volatility95/100

    Top decile vs peers

Watchouts 4

  • Balance sheet6/100

    Current ratio 0.19

  • Cash flow15/100

    -1591% free-cash-flow margin

  • Growth25/100

    Rev -50.2% CAGR · earnings +2.1%

  • Profitability35/100

    -3058% net margin · 0% ROE

Model-based scoring. For information only — not financial advice.

What is Argent BioPharma Limited?

Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer's. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 5.65M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue growth is subdued, limiting near-term earnings expansion.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (38)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap5.65M
P/E RatioN/A
Dividend YieldN/A
52 Week High0.153
52 Week Low0.0105
Last AnnualJune
IPO DateN/A
IncorporatedUSA
Shares Outstanding87M
No. of EmployeesN/A
IndustryDrug Manufacturers - Specialty & Generic
ExchangePINK
Beta0.064
CurrencyUSD · Reports in AUD